#1 Clinical Trials Search in Europe

Peripheral primitive neuroectodermal tumour of soft tissue – Diagnostics

Go back

Diagnosing peripheral primitive neuroectodermal tumor of soft tissue requires a careful combination of imaging tests and detailed tissue analysis. Because this rare and aggressive tumor shares features with other cancers, accurate identification is essential for planning the right treatment approach.

Introduction: When to Seek Diagnostic Testing

If you or someone you know experiences persistent pain, unexplained swelling, or notices a growing lump—especially in the chest, abdomen, pelvis, or limbs—it’s important to consult a healthcare provider. Peripheral primitive neuroectodermal tumors, also known as pPNETs, are rare cancerous tumors that develop in soft tissue and bone, away from the brain and spinal cord. These tumors most commonly affect children, teenagers, and young adults, with many cases diagnosed between ages 10 and 25.[1][2]

Because pPNETs grow quickly and can spread to other parts of the body, early diagnosis is crucial. The symptoms vary depending on where the tumor develops, but common signs include bone pain that comes and goes or worsens at night, swelling around bones or soft tissues, lumps that feel warm to the touch, and unexplained fever or weight loss.[3] If a tumor presses against nearby organs or structures—such as the intestines or lungs—it can cause additional symptoms like abdominal pain, fluid buildup, or difficulty breathing.[3]

Anyone experiencing these symptoms should not delay seeking medical attention. While these signs can be caused by many less serious conditions, timely evaluation helps rule out serious diseases like pPNET. Young people who develop unexplained lumps, persistent pain, or swelling that doesn’t improve with rest should be examined by a doctor, especially if the symptoms last more than a few weeks.

⚠️ Important
Because pPNETs are so rare and share features with other cancers, early and accurate diagnosis is vital. About 18% of patients already have cancer that has spread to other organs when they are first diagnosed.[2] The sooner a diagnosis is made, the sooner treatment can begin, which may improve outcomes.

Classic Diagnostic Methods

Diagnosing a peripheral primitive neuroectodermal tumor involves multiple steps. Doctors use a combination of physical examination, imaging tests, and laboratory analysis of tissue samples. No single test can confirm pPNET on its own—accurate diagnosis requires putting together information from several sources.

Physical Examination and Initial Assessment

The diagnostic process typically begins with a physical exam. The doctor will ask about symptoms, how long they’ve been present, and whether there’s a family history of cancer. During the exam, the doctor may feel for lumps or areas of swelling, check for tenderness, and look for other signs such as fever or weight loss. However, because the symptoms of pPNET can mimic many other conditions—including infections or benign growths—imaging tests are always needed to get a clearer picture.[3]

Imaging Tests

Imaging studies are essential for detecting and evaluating pPNET. These tests allow doctors to see the size, location, and characteristics of the tumor, and to check whether it has spread to other parts of the body.

Magnetic resonance imaging (MRI) is one of the most commonly used tests. MRI scans use magnets and radio waves to create detailed pictures of soft tissues. On an MRI, pPNETs usually appear as a single mass, though they may contain fluid-filled pockets called cysts and show swelling in the surrounding tissue.[3] The tumors typically look similar in brightness to normal tissue on certain images (called T1-weighted images), but may appear slightly brighter on others (T2-weighted images).[6] Most pPNETs are large—averaging around 12 to 13 centimeters in diameter—and have irregular shapes with poorly defined borders.[2][6]

Computed tomography (CT) scans are also frequently used. CT scans use X-rays to create cross-sectional images of the body. On CT, pPNETs often show as masses with uneven areas inside—some parts may be solid, while others contain small areas of dead tissue, known as necrosis. When a contrast dye is injected into the bloodstream before the scan, the tumor typically shows uneven brightening, meaning some parts absorb more dye than others.[6] This pattern helps doctors distinguish pPNET from other types of tumors.

Positron emission tomography (PET) scans may also be performed, sometimes combined with CT. PET scans use a small amount of radioactive sugar to highlight areas where cells are growing rapidly—such as cancer cells. Tumors like pPNET absorb large amounts of this sugar, which shows up as bright spots on the scan. This test is particularly useful for detecting whether the cancer has spread to distant parts of the body, such as the lungs or bones.[8]

Biopsy and Tissue Analysis

While imaging can suggest the presence of a tumor, a definitive diagnosis requires examining a sample of the tumor tissue under a microscope. This procedure is called a biopsy. The sample can be obtained in several ways: through a needle inserted into the tumor, during surgery to remove part or all of the tumor, or through other minimally invasive techniques.[3]

A specialist called a neuropathologist or pathologist examines the tissue. Under the microscope, pPNETs are made up of small, round cells that are tightly packed together. A distinctive feature is the presence of structures called rosettes, where multiple cells arrange themselves in a circle around a central point, resembling the petals of a rose.[3][5] These patterns, along with other microscopic features, help identify the tumor as a pPNET rather than another type of cancer.

Immunohistochemical Testing

To confirm the diagnosis, pathologists perform additional tests on the tissue sample called immunohistochemistry. This technique uses special stains that react with proteins on the surface of tumor cells. The most important marker for pPNET is a protein called CD99, which is present in 90% to 100% of cases.[3][5] Other markers that suggest the involvement of nerve cells—called neural markers—must also be positive. At least two of these markers need to be present to make a diagnosis of pPNET.[5]

Pathologists also test for markers that would indicate other types of cancer, such as those affecting the skin, lymph nodes, muscles, or other tissues. If those markers are negative and CD99 is strongly positive, it supports the diagnosis of pPNET.[5]

Genetic and Molecular Testing

One of the most specific tests for pPNET is looking for genetic changes in the tumor cells. Most pPNETs have a characteristic chromosomal translocation—a rearrangement where pieces of two chromosomes swap places. The most common translocation involves chromosomes 11 and 22, creating a fusion of two genes called EWSR1 and FLI1.[1][5] This genetic change can be detected using a laboratory technique called fluorescence in situ hybridization (FISH) or other molecular methods.[8]

Finding this genetic signature helps confirm the diagnosis and distinguishes pPNET from other cancers that look similar under the microscope, such as rhabdomyosarcoma, neuroblastoma, or lymphoma.[1] Because these cancers require different treatments, accurate genetic testing is critical.

Staging and Assessment of Spread

Once the diagnosis is confirmed, doctors need to determine how far the cancer has spread—a process called staging. Additional imaging tests, such as chest CT scans, bone scans, or whole-body MRI, may be performed to check for metastasis—the spread of cancer to other organs. The most common sites of spread are the lungs, bones, and bone marrow.[5][2]

In some cases, doctors may perform a bone marrow biopsy to check whether cancer cells have reached the bone marrow. Staging helps doctors plan the most appropriate treatment and provides information about the likely course of the disease.

Diagnostics for Clinical Trial Qualification

Patients with pPNET may be offered the opportunity to participate in clinical trials—research studies testing new treatments. To join a trial, patients must meet specific criteria, and certain diagnostic tests are required to confirm eligibility.

Confirmation of Diagnosis

Before enrolling in a clinical trial, the diagnosis of pPNET must be confirmed through both histological examination (looking at tissue under a microscope) and immunohistochemical testing. Trials typically require that the tumor shows the characteristic CD99 marker and has the genetic translocation involving the EWSR1 gene.[1][5] This ensures that all participants truly have the same type of cancer, making the trial results more reliable.

Baseline Imaging and Laboratory Tests

Before starting treatment in a trial, patients undergo a series of baseline tests to document the size and extent of their tumor. These typically include MRI or CT scans of the primary tumor and areas where the cancer might have spread. PET scans may also be required.[8] These images serve as a reference point to measure how well the experimental treatment is working.

Laboratory tests are also performed to assess the patient’s overall health and organ function. Blood tests check the function of the kidneys, liver, and bone marrow. Because many cancer treatments can affect these organs, doctors need to know if they are working properly before treatment begins. Tests may include complete blood counts, kidney function tests, liver enzyme levels, and other markers of general health.

Assessment of Tumor Size and Metastasis

Tumor size is an important factor in clinical trial eligibility. Many studies only accept patients whose tumors are a certain size or who have not yet developed metastasis. Conversely, some trials specifically study treatments for advanced cancer that has already spread. Imaging tests and sometimes surgical samples are used to measure the tumor accurately and check for distant spread.[2][5]

Monitoring During Treatment

Once enrolled in a trial, patients undergo regular diagnostic tests to monitor their response to treatment. Imaging studies are repeated at scheduled intervals—often every few weeks or months—to see whether the tumor is shrinking, staying the same size, or growing. Blood tests are also repeated to watch for side effects and ensure that organs are tolerating the treatment.[5]

These ongoing assessments help researchers understand whether the new treatment is effective and safe. They also allow doctors to adjust the treatment plan if needed, such as changing the dose or adding other therapies.

⚠️ Important
Clinical trials offer access to new treatments that are not yet widely available. However, participation requires meeting strict diagnostic criteria and undergoing thorough testing. If you or a loved one is interested in a clinical trial for pPNET, talk to your healthcare team about whether this option is appropriate and what tests will be needed.

Prognosis and Survival Rate

Prognosis

The outlook for patients with peripheral primitive neuroectodermal tumor of soft tissue depends on several factors. Patients with smaller tumors, no spread to other organs at the time of diagnosis, and those who receive aggressive treatment combining surgery, chemotherapy, and sometimes radiation tend to have better outcomes.[2][5] Unfortunately, pPNET is an aggressive cancer, and the prognosis is generally considered poor compared to some other types of cancer.[1]

Tumor size is one of the most important factors affecting prognosis. Patients with large tumors—especially those larger than 10 centimeters—face a higher risk of the cancer spreading and poorer survival.[2][5] Patients who already have metastasis (spread to the lungs, bones, or other organs) at the time of diagnosis also have worse outcomes.[2] Other factors that may influence prognosis include the patient’s age, the location of the tumor, and whether the tumor can be completely removed with surgery.[5]

Patients who receive multimodal therapy—meaning a combination of surgery, chemotherapy, and sometimes radiation—tend to have better survival than those treated with only one type of therapy.[2][5] Complete surgical removal of the tumor (called R0 resection) is associated with improved survival, as is receiving more than 10 cycles of chemotherapy.[5] These findings emphasize the importance of intensive, coordinated treatment from a team of specialists.

Survival Rate

Survival rates for pPNET vary depending on the stage of the disease and the treatment received. In one large study of 89 patients, the median overall survival was 15 months, meaning half of the patients lived longer than this and half lived less.[2] The 3-year survival rate was 32%, and the 5-year survival rate was 25%.[2] This means that about one-quarter of patients were still alive five years after diagnosis.

However, survival can be better for patients with favorable characteristics. Those with small tumors, no metastasis at diagnosis, and complete surgical removal of the tumor have higher survival rates. In contrast, patients with large tumors or cancer that has already spread have much lower survival rates.[2][5]

It’s important to remember that survival statistics are based on groups of patients and cannot predict what will happen to any individual person. Advances in treatment, including new chemotherapy regimens and clinical trials, continue to improve outcomes. Each patient’s situation is unique, and survival depends on many factors, including response to treatment and overall health.

Ongoing Clinical Trials on Peripheral primitive neuroectodermal tumour of soft tissue

  • Study to Find the Right Dose and Safety of Lutetium (177Lu) Edotreotide and Arginine-Lysine in Children with Somatostatin Receptor-Positive Tumors

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

References

https://emedicine.medscape.com/article/855644-overview

https://pmc.ncbi.nlm.nih.gov/articles/PMC6865547/

https://www.medicalnewstoday.com/articles/peripheral-neuroectodermal-tumor

https://www.ncbi.nlm.nih.gov/books/NBK562165/

https://www.nature.com/articles/s41598-020-72680-6

https://www.oncotarget.com/article/2649/text/

https://www.ebsco.com/research-starters/health-and-medicine/neuroectodermal-tumors

https://surgicalcasereports.springeropen.com/articles/10.1186/s40792-015-0084-7

More information about
Peripheral primitive neuroectodermal tumour of soft tissue:

FAQ

What is the first test done if a doctor suspects pPNET?

The first step is usually an imaging test, such as an MRI or CT scan, to visualize the tumor and assess its size and location. If the imaging suggests a tumor, a biopsy is then performed to examine the tissue under a microscope and confirm the diagnosis.[3][6]

Can pPNET be diagnosed with a blood test alone?

No. While blood tests are used to assess overall health and organ function, pPNET cannot be diagnosed from blood alone. A tissue sample from the tumor is required for microscopic examination and genetic testing to confirm the diagnosis.[3][5]

How accurate are imaging tests in diagnosing pPNET?

Imaging tests like MRI and CT scans are very helpful in detecting tumors and understanding their characteristics, but they cannot definitively diagnose pPNET. A biopsy and laboratory analysis—including immunohistochemical and genetic testing—are necessary to confirm the diagnosis.[3][6]

What makes pPNET difficult to diagnose?

pPNET is rare and looks very similar under the microscope to other cancers that are made up of small, round cells, such as lymphoma, neuroblastoma, and rhabdomyosarcoma. Special tests—including immunohistochemistry and genetic analysis—are needed to distinguish pPNET from these other cancers.[1][5]

How long does it take to get a final diagnosis?

The time required depends on the complexity of the tests. Imaging results are usually available within a few days, but biopsy results—including immunohistochemistry and genetic testing—can take one to two weeks or longer. Your healthcare team will keep you informed throughout the process.

🎯 Key Takeaways

  • • Peripheral primitive neuroectodermal tumors are rare cancers that require a combination of imaging, biopsy, and genetic testing for accurate diagnosis.
  • • The presence of the CD99 protein and a specific chromosomal translocation involving chromosomes 11 and 22 are hallmarks of pPNET.
  • • Imaging tests like MRI, CT, and PET scans help visualize the tumor, but a tissue biopsy is essential to confirm the diagnosis.
  • • Early detection is critical—about 18% of patients already have cancer that has spread when they are first diagnosed.
  • • Tumor size, presence of metastasis, and whether the tumor can be completely removed are key factors affecting prognosis and survival.
  • • Clinical trials require thorough diagnostic testing to confirm eligibility and monitor response to new treatments.
  • • Survival rates for pPNET are challenging, but patients who receive aggressive multimodal treatment—including surgery, chemotherapy, and sometimes radiation—tend to have better outcomes.
  • • Genetic testing not only confirms the diagnosis but also helps distinguish pPNET from other similar-looking cancers, ensuring patients receive the most appropriate treatment.

Connected medications: